Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

Regeneron Pharmaceuticals Inc. (NASDAQ ... in treating moderate-to-severe atopic dermatitis/AD in adolescents and adults with skin of color. These findings were presented at the 2025 ...

Paris: Sanofi has successfully priced its offering of euro 1.5 billion of notes across 2 tranches:€750 million fixed-rate ...

Regeneron Pharmaceuticals ... It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced ...

Compared with other systemic agents for treating atopic dermatitis, dupilumab is associated with an increased risk for ...

PORTLAND, OR, UNITED STATES, June 18, 2025 /EINPresswire.com/ -- The global atopic dermatitis market is witnessing unprecedented growth, projected to expand from $5.3 billion in 2021 to $22.6 billion ...

Key findings of subgroup analyses included an observed increased psoriasis risk in patients without atopic comorbidities (HR 1.42, 95% CI 1.06-1.89) and those with pretreatment immunoglobulin E (IgE) ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

Ruxolitinib 0.75% cream and ruxolitinib 1.5% cream are effective and well-tolerated in children aged 2 to 11 years with atopic dermatitis.

Outcomes were evaluated among children born between April 1980 and June 2019 by using data from 12 observational birth ...